Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Liabilities for 7 consecutive years, with $242.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 34.42% to $242.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $242.8 million through Dec 2025, down 34.42% year-over-year, with the annual reading at $242.8 million for FY2025, 34.42% down from the prior year.
  • Total Liabilities for Q4 2025 was $242.8 million at Beam Therapeutics, down from $345.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $647.7 million in Q4 2021, with the low at $242.8 million in Q4 2025.
  • Average Total Liabilities over 5 years is $451.8 million, with a median of $426.7 million recorded in 2024.
  • The sharpest move saw Total Liabilities skyrocketed 398.21% in 2021, then crashed 34.42% in 2025.
  • Over 5 years, Total Liabilities stood at $647.7 million in 2021, then dropped by 6.09% to $608.2 million in 2022, then fell by 21.35% to $478.4 million in 2023, then dropped by 22.6% to $370.3 million in 2024, then plummeted by 34.42% to $242.8 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $242.8 million, $345.1 million, and $344.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.